+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment of Refractory Uveitis Patients With Subconjunctival Interferon Alfa

Treatment of Refractory Uveitis Patients With Subconjunctival Interferon Alfa

ARVO Annual Meeting Abstract Search & Program Planner : Abstract No 4276

Purpose: Interferon alfa (IFN-alfa) is a very potent drug with immunomodulatory, antiproliferative and antiinflammatory properties which can also be toxic with effective systemic doses. We used IFN-alfa given subconjunctivally in a low dose regimen to treat refractory cases of uveitis who did not benefit from standart therapeutical procedures. Methods: We treated eleven uveitis-patients with IFN-alfa with subconjunctival administration. Two patients had herpetic anterior uveitis and one patient had pars planitis. Four patients were diagnosed with posterior uveitis (2 cases of serpiginous choroidopathy, 1 case of toxoplasmic chorioretinitis, 1 case of presumed ocular histoplasmosis) whereas four patients had panuveitis (2 cases with Behcet disease). We used 1 M IU IFN -alfa two to three times in a week to a total of 20 to 30 subconjunctival injections repeated as necessary. Five patients were using topical and/or local steroids during IFN-alfa applications. Results: All patients showed varying degree of uveitis regression. Two patients with panuveitis and three patients with posterior uveitis had complete regression of uveitis (follow-up time: 3 to 8 years). Other patients had remarkable suppression of the uveitic reactions for 6 to 30 months. Conclusion: Interferon alfa administred subconjunctivally in a lower dose regimen seems to be safe and effective to modulate uveitic reactions of the eye.

(PDF emailed within 1 workday: $29.90)

Accession: 035980598

Download citation: RISBibTeXText

Related references

Natural alfa interferon treatment of chronic hepatitis C in patients refractory to recombinant interferon alfa 2B. Hepatology 22(4 PART 2): 117A, 1995

Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease. Yonsei Medical Journal 56(4): 1158-1162, 2015

Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina 26(7): 786-791, 2006

Low dose and dose escalating therapy of interferon alfa-2a in the treatment of refractory and sight-threatening Behçet's uveitis. Clinical and Experimental Rheumatology 27(2 Suppl 53): S113-S114, 2010

Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease. Ocular Immunology and Inflammation 8(4): 293-301, 2001

Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behet's disease. Ocular Immunology & Inflammation 8(4): 293-301, 2000

Effect of Interferon alfa-2a Treatment on Adaptive and Innate Immune Systems in Patients With Behçet Disease Uveitis. Investigative Ophthalmology & Visual Science 60(1): 52-63, 2019

Interferon alpha-2a treatment for refractory Behcet uveitis in Korean patients. Bmc Ophthalmology 18(1): 52-52, 2018

Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa. British Journal of Ophthalmology 79(2): 150-152, 1995

Safety and efficacy of interferon-alfa and interferon-alfa plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients under HAART. Hepatology 32(4 Pt 2): 555A, October, 2000

Alfa interferon 2B and ribavirin for treatment of patients with chronic hepatitis C who have failed alfa interferon 2B as single therapy. Hepatology 28(4 PART 2): 284A, 1998

A randomized study of Ribavirin plus interferon alfa vs interferon alfa alone for treatment of patients with chronic hepatitis C. Hepatology 30(4 PART 2): 621A, 1999

The retreatment with natural leukocyte interferon alfa-n3 of chronic hepatitis C patients: the intolerant and nonresponsive results to prior treatment with recombinant alfa interferon. Annali Italiani di Medicina Interna 14(3): 159-165, 1999

Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis. Archives of Ophthalmology 129(3): 288-294, 2011

Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments. Ophthalmology 117(7): 1430-1435, 2010